IM CannabisIMCC -10.70%36 Days Payable is 126.90 as of Mar. 2026, which is 24% above its 10-year median of 102.33. GuruFocus rates IMCC with a GF Score™ of 36/100 and a GF Value™ of $1.39 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 923 Drug Manufacturers companies, IM Cannabis ranks better than 89.6% on this metric.
The historical rank and industry rank for IM Cannabis's Days Payable or its related term are showing as below:
IMCC'
s Days Payable Range Over the Past 10 Years
Min: 83.9 Med: 102.33 Max: 262.92
Current: 262.92
During the past 13 years, IM Cannabis's highest Days Payable was 262.92. The lowest was 83.90. And the median was 102.33.
IMCC's Days Payable is ranked better than 89.6% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs IMCC: 262.92
IM Cannabis's Days Payable
increased
from Dec. 2024 (122.39) to Mar. 2026 (126.90).
It may suggest that IM Cannabisdelayed paying its suppliers.
IM Cannabis Days Payable Related Terms
IM Cannabis Days Payable Historical Data
* Premium members only.
The historical data trend for IM Cannabis's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, IM Cannabis's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IM Cannabis Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IM Cannabis's Days Payable distribution charts can be found below:
* The bar in red indicates where IM Cannabis's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
IM Cannabis's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IM Cannabis (IMCC) has a Days Payable of 126.90 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on IM Cannabis and its competitors. This is 24% above median its historical median of 102.33. Over the past decade, IM Cannabis' Days Payable has ranged from 83.90 to 262.92. According to the industry distribution chart, IM Cannabis ranks #96 out of 923 companies in the Drug Manufacturers industry, placing it in the top 10.4%.
Is IM Cannabis' Days Payable too high?
IM Cannabis' current Days Payable of 126.90 is 24% above median its 10-year median of 102.33. Over the past 10 years, this metric has ranged from a low of 83.90 to a high of 262.92. The Drug Manufacturers industry median Days Payable is 90.98. IM Cannabis' value of 126.90 is 39.5% above this industry median. Based on the distribution chart, IM Cannabis ranks #96 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, IM Cannabis has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IM Cannabis' Days Payable compare to CPMD and SKYI?
According to the Drug Manufacturers industry distribution chart, IM Cannabis ranks #96 out of 923 companies for Days Payable. This places IM Cannabis in the top 10% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. IM Cannabis' value of 126.90 is 39.5% above this benchmark. Historically, IM Cannabis' own Days Payable has ranged from 83.90 to 262.92 over the past decade. While the company's 10-year median is 102.33 vs. the industry median of 90.98, IM Cannabis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IM Cannabis's current Days Payable of 126.90 is 39.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on IM Cannabis and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IM Cannabis's current Days Payable is 126.90, which is 24% above median its own 10-year median of 102.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IM Cannabis stock overvalued right now?
Based on GuruFocus' analysis, IM Cannabis (IMCC) is currently considered Possible Value Trap. The stock's GF Value™ is $1.39, compared to a current price of $0.14 — trading 89.8% below its estimated fair value. The current Days Payable is 126.90, which is 24% above median its 10-year median of 102.33 and 39.5% above the Drug Manufacturers industry median of 90.98. IM Cannabis' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For IM Cannabis (IMCC), the current Days Payable is 126.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IM Cannabis (IMCC) Overvalued in 2026?
Based on GuruFocus' analysis, IM Cannabis stock appears to be undervalued.
The current stock price of $0.14 is trading 89.8% below its estimated GF Value™ of $1.39.
GuruFocus considers IM Cannabis to be Possible Value Trap.
Key valuation signals for IMCC:
Days Payable: 126.90 (24% above median its 10-year median of 102.33)
GF Value™: $1.39 vs. price of $0.14 (89.8% below fair value)
Industry Position: 39.5% above the Drug Manufacturers median (#96 of 923)
No single metric tells the full story. See the IMCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority revenue is generated from Germany, and also has its presence in Israel.
36GF Score
Get the complete analysis for IMCC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMCC has been successfully added to your 
